Daryl Drummond, Ph.D. has been appointed head of research at Merrimack Pharmaceuticals. Dr. Drummond has expertise in the field of nanotherapeutics and has held various leadership roles at Merrimack, most recently as vice president of Discovery and team leader for Merrimack’s early-stage pipeline. Dr. Drummond was also integral in the development of ONIVYDE, which was recently sold to Ipsen for as much as $1.0 billion. “Daryl’s successful track record of advancing programs f...